Clinical significance of T cell metabolic reprogramming in cancer
Christoph Herbel(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Nikolaos Patsoukis(Beth Israel Deaconess Medical Center), Pankaj Seth(National Brain Research Centre), Kankana Bardhan(Seres Therapeutics (United States)), Jessica D. Weaver(Beth Israel Deaconess Medical Center)
Cited by 95
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859